NRX Pharmaceuticals, Inc. - NRXP STOCK NEWS

NRx Pharmaceuticals (Nasdaq: NRXP) announced the validation of the first commercial formulation of ZYESAMI™ (aviptadil) for intravenous use, enabling high-volume manufacture with over one year of stability. The company has achieved a 30-to-50-fold increase in aviptadil lot size and a 90% reduction in peptide supply costs. These advancements position NRx to potentially deliver millions of doses as they seek Emergency Use Authorization in various regions amidst ongoing COVID-19 challenges.

NRx Pharmaceuticals (Nasdaq: NRXP) will present findings on ZYESAMI™ (aviptadil) at the Disease Control and Prevention Summit on July 21, 2021. The results from a phase 2b/3 trial demonstrate ZYESAMI™ significantly prevents cytokine storms, which are linked to COVID-19 mortality. In contrast to placebo, patients treated with ZYESAMI™ showed a minimal rise in interleukin 6 levels and a significant drop in 60-day mortality rates. The company is seeking Emergency Use Authorization from the FDA based on these findings.

NRx Pharmaceuticals (Nasdaq: NRXP) announced a Memorandum Of Understanding with the Government of Israel to license worldwide rights for the development and commercialization of the BriLife™ Coronavirus vaccine, developed by the Israel Institute for Biological Research (IIBR). This vaccine, based on a previously FDA-approved platform, promises rapid manufacturing and affordability. NRx plans to deliver doses for the Israeli population and will collaborate with IIBR, which will receive milestone payments. The initiative aims to address challenges posed by Coronavirus mutations and improve global vaccine accessibility.

NRx Pharmaceuticals and Quantum Leap Healthcare Collaborative have commenced treatment of severely ill COVID-19 patients with inhaled ZYESAMI (Aviptadil) in the I-SPY COVID Trial. This Phase 2 trial focuses on assessing multiple agents simultaneously to reduce mortality and mechanical ventilation needs in these patients. Initial results from intravenous ZYESAMI indicate improved 60-day survival rates. The trial also aims to evaluate the potential efficacy of nebulized ZYESAMI, with the support of BARDA and the Department of Defense.

NRx Pharmaceuticals (Nasdaq: NRXP) announced the initiation of clinical training for ICU physicians in Georgia on using intravenous ZYESAMI™ (Aviptadil-acetate) for emergency COVID-19 treatment. Additionally, the ongoing phase 2/3 trial for inhaled ZYESAMI™ will be extended to Georgia and potentially neighboring countries. Clinical drug supplies are expected to ship within two weeks. The partnership is partially funded through Relief Therapeutics. ZYESAMI™ aims to address COVID-19-related respiratory failure by targeting cellular mechanisms affected by the virus.

NRx Pharmaceuticals (Nasdaq: NRXP) reported positive outcomes from the Expanded Access Protocol (EAP) for ZYESAMI™ (Aviptadil) on June 15, 2021. Among 240 patients treated, 53% were alive or discharged at 28 days, with 76% of those on high-flow nasal cannula (HFNC) compared to 54% on mechanical ventilation. This data supports the drug’s efficacy in critically ill COVID-19 patients, as many participants were ineligible for the standard trial. Adverse events included diarrhea and hypotension, consistent with earlier phase trials. NRx is advancing ZYESAMI™ to gain regulatory approval.

NRx Pharmaceuticals (Nasdaq: NRXP) has applied for Emergency Use Authorization (EUA) from the FDA for its drug, ZYESAMI™ (Aviptadil-acetate), aimed at treating critically ill COVID-19 patients with respiratory failure.

The study revealed a significant improvement in patient survival and reduced hospital stays compared to a placebo. Enrolled were 196 participants, and the findings support ZYESAMI™ as the first medication showing effectiveness for patients in advanced stages of COVID-19. The clinical trial had positive implications for patient recovery despite prior treatments.

NRx Pharmaceuticals (Nasdaq: NRXP) has announced the election of H.R. McMaster, retired Lieutenant General and former National Security Advisor, to its Board of Directors, effective May 27, 2021. McMaster's extensive military background and his current roles at Stanford University position him to contribute to NRx’s mission of accelerating therapies for patients with critical illnesses. The company also plans to seek Emergency Use Authorization for treatments related to Covid-19 and is advancing NRX-101 for suicidal bipolar depression, currently in Phase 3 trials.

NRx Pharmaceuticals (Nasdaq: NRXP) has signed a master services agreement with Cromos Pharma to conduct phase 3 clinical trials for COVID-19 treatments in Central Europe and the Caucasus Region. This initiative targets a population of over 500 million, many of whom lack access to effective treatments. Aimed at reducing hospitalization rates, NRx plans to complete trials for its inhaled drug, ZYESAMI™, by September 2021. The collaboration involves significant regional healthcare authorities and aims to address critical healthcare needs following discussions with government officials.